Dendritic cell, the immunotherapeutic cell for cancer

Indian Journal of Medical Research

Volumn 119, Issue 4, 2004, Pages 133-138

  Nagaraj, S ^a   Ziske, C ^a   Schmidt Wolf, I G H ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Dendritic cell; Immunotherapy; Peptide; Transfection; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; ALPHA FETOPROTEIN; ALPHA INTERFERON; CANCER VACCINE; CD11B ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; DNA VACCINE; EPITOPE; GAMMA INTERFERON; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELAN A; MELANOMA ANTIGEN; MONOPHENOL MONOOXYGENASE; NUCLEIC ACID; PEPTIDE; PROSTAGLANDIN E2; RNA; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CLINICAL STUDY; CLINICAL TRIAL; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; DRUG RESEARCH; GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MALIGNANT NEOPLASTIC DISEASE; METHODOLOGY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; REVIEW; SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM;

ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PEPTIDES; TRANSFECTION; VACCINES;

EID: 2442612853     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973; 137 : 1142-62.
2. Shurin MR. Dendritic cells presenting tumor antigen. Cancer Immunol Immunother 1996; 43 : 158-64.
3. Reay PA. Dendritic cells: immunological features and utilisation for tumour immunotherapy. Expert Opin Ther Targets 2001; 5 : 491-506.
4. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392 : 245-52.
5. Banchereau J, Paczesny S, Blanco P, Bennett L, Pascual V, Fay J, et al. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann N Y Acad Sci 2003; 987 : 180-7.
6. Ito T, Amakawa R, Kaisho T, Hemmi H, Tajima K, Uehira K, et al. Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med 2002; 195 : 1507-12.
7. Dzionek A, Fuchs A, Schmidt P, Cremer S, Zysk M, Miltenyi S, et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 2000; 165 : 6037-46.
8. Dzionek A, Inagaki Y, Okawa K, Nagafune J, Rock J, Sohma Y, et al. Plasmacytoid dendritic cells: from specific surface markers of specific cellular functions(1). Hum Immunol 2002; 63 : 1133-48.
9. Ito T, Inaba M, Inaba K, Toki J, Sogo S, Iguchi T, Adachi Y, et al. ACD1a+/CD11c+ subset of human blood dendritic cells is a direct precursor of Langerhans cells, J Immunol 1999; 163 : 1409-19.
10. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000; 18 : 245-73.
11. Marten A, Greten T, Ziske C, Renoth S, Schottker B, Buttgereit P, et al. Generation of activated and antigen-specific T cells with cytoxic activity after co-culture with dendritic cells. Cancer Immunol Immunother 2002; 51 : 25-32.
12. Zhang W, Chen Z, Li F, Kamencic H, Juurlink B, Gordon JR, et al. Tumour necrosis factor-alpha (TNF-alpha) transgene-expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T-cell activation and anti-tumour immunity than DCs generated in recombinant TNF-alpha. Immunology 2003; 108 : 177-88.
13. Mortarini R, Anichini A, Di Nicola M, Siena S, Bregni M, Belli F, et al. Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Cancer Res 1997; 57 : 5534-41.
14. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179 : 1109-18.
15. Zhou LJ, Tedder TF. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA 1996; 93 : 2588-92.
16. Bender A, Sapp M, Schuler G, Steinman RM, Bhardwai N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods 1996; 196 : 121-35.
17. Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B, et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 1996; 196 : 137-51.
18. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180 : 83-93.
19. Lutz MB, Schnare M, Menges M, Rossner S, Rollinghoff M, Schuler G, et al. Differential functions of IL-4 receptor types I and II for dendritic cell maturation and IL-12 production and their dependency on GM-CSF. J Immunol 2002; 169 : 3574-80.
20. Berger TG, Feuerstein B, Strasser E, Hirsch U, Schreiner D, Schulder G, et al. Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories. J Immunol Methods 2002; 268 : 131-40.
21. Nestle FO, Banchereau J, Hart D. Dendritic cells: On the move from bench to bedside. Nature Med 2001; 7 : 761-5.
22. Nestle FO. Dendritic cell vaccination for cancer therapy. Oncogene 2000; 19 : 6673-9.
23. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997; 9 : 10-6.
24. Palucka KA, Taquet N, Sanchez-Chapuis F, Gluckman JC. Dendritic cells as the terminal stage of monocyte differentiation. J Immunol 1998; 160 : 4587-95.
25. Gregoire M, Ligeza-Poisson C, Juge-Morineau N, Spisek R. Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia. Vaccine 2003; 21 : 791-4.
26. Pawelec G, Engel A, Adibzadeh M. Prerequisites for the immunotherapy of cancer. Cancer Immunol Immunother 1999; 48 : 214-7.
27. Gunzer M, Janich S, Varga G, Grabbe S. Dendritic cells and tumor immunity. Semin Immunol 2001; 13 : 291-302.
28. Thumann P, Moc I, Humrich J, Berger TG, Schultz ES, Schulder G. Antigen loading of dendritic cells with whole tumor cell preparations. J Immunol Methods 2003; 277 : 1-16.
29. Stingl G, Bergstresser PR. Dendritic cells: a major story unfolds. Immunol Today 1995; 16 : 330-3.
30. Reinhard G, Marten A, Kiske SM, Feil F, Bieber T, Schmidt-Wolf IG. Generation of dendritic cell-based vaccines for cancer therapy. Br J Cancer 2002; 86 : 1529-33.
31. Armstrong AC, Eaton D, Ewing JC. Science, medicine, and the future: Cellular immunotherapy for cancer. BMJ 2001; 323 : 1289-93.
32. Murphy GP, Tjoa BA, Simmons SJ, Ragde H, Rogers M, Elgamal A, et al. Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 1999; 39 : 54-9.
33. Murphy GP, Tjoa BA, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996; 29 : 371-80.
34. Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Benkoe T, Brostjan C. In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells. Int J Oncol 2003; 22 : 651-6.
35. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001; 50 : 3-15.
36. Onaitis M, Kalady MF, Pruitt S, Tyler DS. Dendritic cell gene therapy. Surg Oncol Clin N Am 2002; 11 : 645-60.
37. Berger TG, Schultz ES. Dendritic cell-based immunotherapy. Curr Top Microbiol Immunol 2003; 276 : 163-97.
38. You Z, Huang X, Hester J, Toh HC, Chen SY. Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res 2001; 61 : 3704-11.
39. Butterfield LH, Jilani SM, Chakraborty NG, Bui LA, Ribas A, Disette VB. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J Immunol 1998; 161 : 5607-13.
40. Butterfield LH, Koh A, Meng W, Vollmer CM, Ribas A, Disette VB. Generation of human T-cell responses to an HLA-A2. 1-restricted peptide epitope derived from aplha-fetoprotein. Cancer Res 1999; 59 : 3134-42.
41. Nair SK, Morse M, Boczkowski D, Cumming RL, Vasovic L, Gilboa E. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg 2002; 235 : 540-9.
42. Sullenger BA, Gibola E. Emerging clinical applications of RNA. Nature 2002; 418 : 252-8.
43. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9 : 271-96.
44. Reid DC. Dendritic cells and immunotherapy for malignant disease. Br J Haematol 2001; 112 : 874-87.
45. Celis E. Getting peptide vaccines to work; just a matter of quality control? J Clin Invest 2002; 110 : 1765-8.
46. Terando A, Chang AE. Applications of gene transfer to cellular immunotherapy. Surg Oncol Clin N Am 2002; 11 : 621-43.
47. Engleman EG. Dendritic cell-based cancer immunotherapy. Semin Oncol 2003; 30 : 23-9.
48. Schmidt-Wolf GD, Schmidt-Wolf IGH. Non-viral and hybrid vectors in human gene therapy: an update. Trends Mol Med 2003; 9 : 67-72.
49. Pecher G. DNA-based tumor vaccines. Onkologie 2002; 25 : 528-32.
50. Humrich J, Jenne L. Viral vectors for dendritic cell-based immunotherapy. Curr Top Microbiol Immunol 2003; 276 : 241-59.
51. Rosenberg SA. Progress in human tumour immunology and immunotherapy Nature 2001; 411 : 380-4.
52. Jenne L, Schuler G, Steinkasserer A. Viral vectors for dendritic cell-based immunotherapy. Trends Immunol 2001; 22 : 102-7.
53. Cristiano RJ, Smith LC, Kay MA, Brinkley BR, Woo SL. Hepatic gene therapy: efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex. Proc Natl Acad Sci USA 1993; 90 : 11548-52.
54. Mulders P, Pang S, Dannull J, Kaboo R, Hinkel A, Michel K, et al. Highly efficient and consistent gene transfer into dendritic cells utilizing a combination of ultraviolet-irradiated adenovirus and poly(L-lysine) conjugates. Cancer Res 1998; 58 : 956-61.
55. Srinivas N, Juergen Neuman, Koch N, Schmidt-Wolf IGH. Class II associated invariant chain - C2GnT epitope against pancreatic carcinoma. Mol Ther 2003; 7 : S270.
56. Marten A, Flieger D, Renoth S, Weineck S, Albers P, Compes M. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol lImunother 2002; 51 : 637-44.
57. Marten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients metastatic renal cell carcinoma. Hum Gene Ther 2003; 14 : 483-94.
58. Lemoli RM, Curti A, Fogli M, Ferri E, Baccarani M. The therapeutic role of dendritic cells in cancer immunotherapy. Haematologica 2002; 87 : 62-6.
59. Satthaporn S, Eremin O. Dendritic cells (II) : Role and therapeutic implications in cancer. J R Coll Surg Edinb 2001; 46 : 159-67.
60. Marten A, Ziske C, Schottker B, Renoth S, Weineck S, Buttgereit P. Increase in the immunostimulatory effect of dendritic cells by pulsing with serum derived from pancreatic and colorectal cancer patients. Int J Colorectal Dis 2000; 15 : 197-205.
61. Armstrong AC, Eaton D, Ewing JC. Cellular vaccine therapy for cancer. Expert Rev Vaccines 2002; 1 : 303-16.
62. Cohen EP. DNA-based vaccines for the treatment of cancer -an experimental mode. Trends Mol Med 2001; 7 : 175-9.